Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Isoflavones, primarily found in soy products, have been studied for their potential cardiovascular benefits. The interest in isoflavones stems from epidemiological observations that populations with high soy intake, such as in East Asia, have lower rates of cardiovascular disease (CVD). Isoflavones are classified as phytoestrogens and can exert mild estrogen-like effects, which may influence cardiovascular health.

Multiple randomized controlled trials and meta-analyses have assessed the impact of isoflavone supplementation on cardiovascular risk factors. Some studies suggest isoflavones may modestly reduce total and LDL cholesterol levels and improve endothelial function. For example, a 2011 meta-analysis in the European Journal of Clinical Nutrition found that soy isoflavones led to small but statistically significant reductions in LDL cholesterol. There is also evidence that isoflavones may slightly lower blood pressure in some populations.

However, the overall magnitude of benefit is generally small, and not all studies have found significant effects. Major cardiovascular outcomes (such as heart attack or stroke) have not been conclusively shown to be reduced by isoflavone supplementation. Guidelines from major organizations do not recommend isoflavones as a primary therapy for CVD prevention or treatment.

In summary, while there is some scientific evidence supporting minor cardiovascular benefits from isoflavone supplementation, the effects are modest and not sufficient to serve as a standalone therapy for cardiovascular disease.

More about isoflavone (unspecified)
More about Cardiovascular Disease

Other ingredients used for Cardiovascular Disease

Other health conditions supported by isoflavone (unspecified)

Products containing isoflavone (unspecified)